In recent years, SGLT-2 inhibitors have emerged as a novel class of drugs that show not only significant efficacy in preserving kidney function and reducing cardiovascular risks but also hold potential in improving the quality of life of patients with CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.